Related Experiment Video
Updated: Jul 3, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
Fracture risk in men with congestive heart failure risk reduction with spironolactone
Laura D Carbone1, Jessica D Cross, Syed H Raza
1Department of Veterans Affairs Medical Center, University of Tennessee Health Science Center, Memphis, Tennessee 38163, USA.
Objectives:
The purpose of this study was to determine whether spironolactone use is associated with fractures in men with congestive heart failure (CHF).
Background:
In rats with aldosteronism, spironolactone preserves skeletal strength. However, in humans, the relationship of spironolactone to fractures is not known.
Methods:
The medical records of all male patients with CHF from 1999 to 2005 treated at the Veterans Affairs Medical Center, Memphis, Tennessee, were reviewed (n = 4,735). Odds ratios with 95% confidence intervals of having a fracture associated with spironolactone use were estimated using conditional logistic regression.
Results:
We identified 167 cases with a single-incident fracture and matched these by age and race to 668 control subjects without fractures. After adjustment for covariates, spironolactone use was inversely associated with total fracture (odds ratio: 0.575; 95% confidence interval: 0.346 to 0.955, p = 0.0324).
Conclusions:
The use of spironolactone is inversely associated with fractures in men with CHF.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure V: Medical Management
Heart Failure Drugs: Diuretics
Heart Failure Drugs: β-Blockers
Heart Failure VI: Adjunct Therapies
Mitral Regurgitation IV: Nursing Management